Class I antiarrhythmic drugs
GPTKB entity
Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiarrhythmic drug class
|
| gptkbp:contraindication |
heart block
severe heart failure |
| gptkbp:discoveredBy |
gptkb:Vaughan_Williams
|
| gptkbp:effectOnActionPotential |
decreased slope of phase 0 depolarization
|
| gptkbp:effectOnECG |
widened QRS complex
|
| gptkbp:example |
gptkb:propafenone
gptkb:phenytoin gptkb:lidocaine quinidine disopyramide encainide flecainide mexiletine procainamide |
| https://www.w3.org/2000/01/rdf-schema#label |
Class I antiarrhythmic drugs
|
| gptkbp:mechanismOfAction |
blockade of fast sodium channels
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
hypotension
CNS effects proarrhythmia |
| gptkbp:subclassOf |
Class Ia antiarrhythmic drugs
Class Ib antiarrhythmic drugs Class Ic antiarrhythmic drugs |
| gptkbp:usedFor |
treatment of cardiac arrhythmias
|
| gptkbp:usedIn |
ventricular arrhythmias
supraventricular arrhythmias |
| gptkbp:Vaughan_Williams_classification |
gptkb:Class_I
|
| gptkbp:bfsParent |
gptkb:Class_I
|
| gptkbp:bfsLayer |
4
|